This DHPC letter is to ensure that compatible NFCs are procured in advance, stored and used together with Calcium Chloride Intravenous Infusion, 10% w/v in PFS for the safe use of this product.

This DHPC letter also communicates that a new 10 ml CONNECT syringe glass barrel with a wider internal channel and fixed Luer lock adapter has been introduced to the Aurum Range of Prefilled Syringes, to help HCPs to differentiate between both barrels that will be on the market for an overlapping period, and to remind HCPs of the risks associated with the use of an incompatible NFC and to provide access to the lists of compatible NFCs.

This risk minimisation material is a condition of the marketing authorisation. This Checklist supports the communication of critical tasks and actions throughout the patient’s cycle of treatment with mavacamten; before starting treatment, during treatment, and after treatment has been discontinued.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Please ensure that you carry this card with you at all times.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Embryo-fetal toxicity risk information is presented as a tear-out in the Patient Guide, which can be removed if the risk of embryo-fetal toxicity does not apply.

CAR-T handling guide

Carvykti Physician Guide

Patient Journey Guide

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

This Pharmacist Checklist Quick Guide is provided to assist you in your assessment of a patient’s suitability for Cialis Together. It is designed to be used in conjunction with the Cialis Together Checklist. The Cialis Together Checklist can be provided to the patient to complete before consultation with you or it can be used as part of your consultation with the patient. Use of this material is optional and pharmacists should use their professional judgement to decide when and how to use it.

This Pharmacist Checklist Quick Guide is provided to assist you in your assessment of a patient’s suitability for Cialis Together. It is designed to be used in conjunction with the Cialis Together Checklist. The Cialis Together Checklist can be provided to the patient to complete before consultation with you or it can be used as part of your consultation with the patient. Use of this material is optional and pharmacists should use their professional judgement to decide when and how to use it.

This guide, together with the Cialis Together checklist and Pharmacist Checklist Quick guide (which helps with the interpretation of patients' answers), has been developed by Sanofi to support pharmacists and pharmacy assistants in managing the risks related to Cialis Together and enabling its appropriate supply and use.

After assessing the man, using the Cialis Together Pharmacist Checklist Quick Guide, complete and supply them with either the Repeat Purchase Card or Referral Card by tearing off the appropriate card.

Description: Cibinqo Patient Card

Description: Prescriber brochure to provide guidance on assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]